Introduction
Chronic lymphocytic leukemia (CLL), the most frequent form of leukemia in Western countries, where it accounts for 20-40% of all leukemias, is caused by the accumulation of neoplastic B lymphocytes with a characteristic immunophenotype. This type of leukemia predominates in the elderly, with the median age of patients at diagnosis being close to 70 years. The course of the disease is heterogeneous. Thus, whereas some patients have a survival which is not affected by the disease, others die shortly after diagnosis. [1] [2] [3] Despite some progress in therapy, CLL remains incurable with standard treatments. This, coupled with the advanced age of many patients as well as the relatively indolent course of the disease in a substantial proportion of cases, makes symptom palliation a reasonable treatment goal in many cases. Nevertheless, about one third of the patients are under the age of 60, and 10-15% are younger than 50. In this group of patients, the aim of treatment cannot be merely palliative.
For all these reasons, the number of stem cell transplants performed in individuals with CLL is increasing, 4 in CLL, however, has not been established in clinical trials, and so should still be considered as experimental procedures in this disease.
We report on the clinical outcome and its relationship with minimal residual disease (MRD), as evaluated by cytofluorometry and analysis of the IgH gene rearrangement, in 26 patients with CLL undergoing either autologous (n = 14) or allogeneic (n = 12) stem cell transplantation at our institution.
Patients and methods

Patients
Twenty-six individuals diagnosed with CLL according to the National Cancer Institute-Sponsored Working Group criteria (NCI/WG) 6 undergoing stem cell transplantation (14 autologous, 12 allogeneic) in our institution since 1991 are the subject of the present analysis. Patients up to the age of 60 were offered transplantation if they had active disease with any of the following poor prognostic features: advanced clinical stage (Binet's B or C), rapid doubling time (Ͻ12 months), or a diffuse bone marrow biopsy pattern. [7] [8] [9] [10] [11] [12] Autologous transplant was indicated when a significant response was obtained after chemotherapy. Allogeneic stem cell transplantation was offered to patients under the age of 55 who had an HLA-identical sibling. The main features of the patients upon diagnosis of CLL and at the time of transplant, treatment pre-transplant, as well as the characteristics of the procedure, are summarized in Table 1 . All patients gave informed consent. The Ethics Committee of our institution had approved the clinical trials in which patients were included. The clinical results obtained in the first 12 patients transplanted have already been published. 13 
Minimal residual disease assessment
Immunophenotypic analysis of lymphoid population and molecular studies of the rearrangement pattern of the CDRIII region of the heavy chain immunoglobulin (IgH) were performed at the time of diagnosis and/or before treatment. Analyses were repeated immediately before transplant. Clinical response was assessed at 3 months following HSCT according to the NCI/WG criteria. 6 Relapse was defined as the reappearance of clinical (ie symptoms, lymph node or spleen/liver enlargement), radiological (CT scan) or morphological evidence (peripheral blood and bone marrow, or other tissue in case of extramedullary relapses) of disease after a CR lasting at least 2 months. In patients achieving either a complete response (CR) or a nodular partial response (nPR), MRD was analyzed in both peripheral blood (PB) and bone marrow (BM) samples, whenever possible. MRD status was assessed every 3-4 months during the first year post-transplant and every 6 months afterwards, by means of the techniques detailed below.
Immunophenotypic analysis
Samples were processed using the whole blood method followed by erythrocyte lysis (FACS lysing solution; Becton Dickinson, San José, CA, USA). PB and BM samples were stained with the appropriate amount of monoclonal antibodies (MoAb) in double or triple combinations (CD19-FITC/CD5-PE, CD23-FITC/CD19-PE, kappa-FITC/lambda-PE/CD19-PE-Cy5, CD20-FITC/CD5-PE/CD19-PE-Cy5, CD22-FITC/CD23-PE/ CD19-PE-Cy5). MoAb were purchased from Becton Dickinson (CD19-FITC, CD19-PE, CD20-FITC, CD5-PE, CD23-PE), The 
/CD19
+ cells has been implemented. Any of the following criteria were employed to consider the presence of immunologically detectable MRD:(1) detection of a welldefined and independent population of CD19
+ cells with a bright CD5 expression; (2) a kappa/lambda ratio Ͼ5:1 or Ͻ1:2 but in agreement with the initial diagnosis; and (3) ). The specificity of this threshold was defined after the analysis of their expression in healthy individuals. Moreover, a consistent sensitivity of at minimum 1 × 10 −4 was achieved in all cases after performing dilutional experiments using samples from seven CLL patients.
Molecular analysis
DNA was extracted from PB and BM samples using a sodium chloride extraction method.
14 The rearrangement pattern of IgH was analyzed by means of Southern blot method and PCR of the third complementary region (CDRIII) of the IgH gene. Southern blot analysis was performed on genomic DNA after digestion with the EcoRI and HindIII restriction enzymes and hybridization with a probe of the IgH region. 15 PCR protocol consisted of a seminested reaction with a forward consensus primer of the CDRIII region -FR3A, synthesized by harboring two random nucleotides at highly variable sites -and two reverse primers, LJH and VLJH each one designed for the outer and the inner round, respectively, showing a high homology to 3Ј end of all JH segments. Sequences of primers were obtained from a previously published report, and conditions of cycles were optimized following this assay. 16 Electrophoresis of the PCR product was done in a 4% agarose gel or, for a better definition of the rearrangement pattern, a 12% acrylamide gel if required. 17 The amplification of a discrete band of 80-120 bp of the same size as the one from the diagnostic sample was considered as molecular evidence of MRD. Dilutional experiments performed at our laboratory confirmed a sensitivity of at minimum 10 −3 with this technique, as previously reported. [16] [17] [18] [19] 
Statistical analysis
Comparison between groups was performed by the corrected 2 test. Survival curves were obtained by the method of Kaplan and Meier and compared by the log-rank test.
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Results
Autologous transplantation Disease status at time of transplant:
Fourteen patients were autotransplanted, their main clinical characteristics being shown in Table 1 . In all patients, the immunophenotype of the leukemic cells was consistent with the diagnosis of CLL. In addition, an amplifiable monoclonal IgH band was obtained in all cases. One patient (UPN 6) was transplanted after having attained MRD(−) CR. In another patient who achieved a clinical CR pre-transplant (UPN 23), a residual CLL population was detected by flow cytometry and PCR analyses. MRD was simultaneously detectable by both methods (ie immunophenotypic and molecular biology) in all cases. The results of PCR analysis in the leukapheresis product were totally consistent with those in bone marrow and peripheral blood pre-mobilization in all patients. Thus, MRD was detectable in all except the above mentioned patient having achieved MRD(−) CR before mobilization. In three patients undergoing CD34 + positive selection followed by CD19 + negative selection of the harvest (UPN 15, 17 and 23), the negativization of MRD in the graft was obtained.
Response, transplant-related mortality (TRM), and monitoring of MRD after transplantation:
All 14 patients autografted achieved CR according to the NCI/WG criteria and no patient died as a result of the procedure. At the first evaluation after transplant, nine of the 14 patients (64%) had no detectable MRD, while MRD was present in the remaining five. A bone marrow lymphocytic infiltration Ͼ30% was the only pre-transplant feature associated with MRD(+) status after transplantation (0/3 vs 9/11, P = 0.03). In no case was a delayed clearance of MRD observed, although a moderate and transient decrease in the amount of the CLL population identifiable by cytofluorometry was seen in two patients (UPN 16 and 20) the first semester following transplantation.
During the first year post-transplantation, virtually all MRD(−) patients had, among their CD19 (+) cells, a proportion of CD5
(+) cells exceeding 25%. However, cytofluorometric analysis using three different markers and light chain restriction assessment made possible the differentiation of residual CLL cells from a non-leukemic CD19/CD5 expanded subset. In addition, a B cell polyclonal expansion was observed in one patient (UPN 15) who had received an autologous transplant with a double selected (CD34 + CD19 − ) harvest. The polyclonal nature of lymphoid cells was confirmed by a careful analysis using the above detailed methodology (triple labeling, light chain expression assessment, and studies of IgH rearrangement pattern) (Figure 1 ). In four of the nine patients (UPN 24, 8, 12 and 9) in whom a CR at MRD level was attained, reappearance of residual disease (MRD relapse) was detected at 6, 12, 30 and 42 months after transplant, respectively; this was followed by clinical relapse in two patients (UPN 12 and 24) at 38 and 15 months post-transplant. Moreover, an increase of MRD, as assessed by the quantitative estimation by cytofluorometry of the leukemic population, was evident in further analyses of all patients in whom MRD became detectable. In the remaining five patients, no evidence of MRD was observed at last assessment, after a median follow-up of 24 months (range, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . At the time of writing, six patients have had a clinical relapse at a median of 16 months (range, 9-38) after transplant. Four of these patients did not achieve CR at MRD level (UPN 4, 14, 16 and 20) ; the remaining two patients, MRD(−) initially, became MRD(+) afterwards (UPN 12 and 24) . Disease-free survival was significantly better in the group of patients achieving MRD(−) status post-transplant (median DFS, not reached vs 17, P = 0.02).
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Figure 1
(a) Image of the cytometric analysis in a case of a polyclonal expansion of B lymphocytes in a patient undergoing a purged autotransplant. A clearly unrestricted light chain expression together with the absence of a detectable population with a characteristic CLL phenotype after transplant is shown. In contrast, the vast majority of B lymphocytes analyzed pretransplant corresponded to CLL lymphocytes, with a bright CD5 and concomitant weak CD20 expression. (b) PCR of CDR3 region in the same case. A polyclonal pattern of IgH rearrangement in samples obtained at 3 (lanes 3 and 4), 6 (lanes 5 and 6) and 12 months (lanes 7 and 8) after transplant is shown, in contrast to the discrete band, indicated by an arrow, corresponding to a monoclonal IgH rearrangement from a pre-transplant sample (lane 9). M: molecular size marker.
A summary of the results of analyses of MRD and disease status is shown in Figure 2 . Disease-free survival and the actuarial probability of a negative MRD status after autologous transplantation are shown in Figure 3 . Estimation of the risk of clinical relapse after detection of MRD(+) is of 100% at 26 months.
Allogeneic transplants Disease status at time of transplant:
Twelve patients received an allogeneic transplant from an HLA-identical sibling. In addition to a well-defined CLL population and IgH rearrangement, allowing MRD monitoring, all patients had clinically detectable disease pre-transplant. A bone marrow lymphocytic infiltration Ͼ30% was present in virtually all patients (11/12) prior to the transplant (Table 1) .
Response, TRM, GVHD and monitoring of MRD after trans-
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Figure 2
Results of MRD monitoring after autotransplantation.
Figure 3
Actuarial probability of disease-free survival and MRDfree survival after autologous transplantation.
plantation:
Four patients developed acute GVHD, which was of grade I in one patient (UPN 1), grade II in two patients (UPN 3 and 7) and grade III (UPN 2), refractory to treatment, in another patient. Four patients among 10 patients at risk developed chronic GVHD (UPN 2, 3, 13 and 22). Three patients (25%) died in the early post-transplant period, due to lung aspergillosis in the setting of severe GVHD at 5 months (UPN 2), diffuse alveolar hemorrhage at day +15 (UPN 10), and influenza pneumonia at day +30 (UPN 18), respectively. One patient failed to achieve a significant response (UPN 22). The remaining eight patients achieved CR (67%) between 3 and 6 months post-transplant. Among the eight responding patients, five cases were MRD(−) at the first evaluation after transplant. A delayed molecular response was observed in two clinically responsive patients (UPN 5 and 13) in whom MRD became undetectable at 12 and 22 months after transplant, respectively, and was coincidental with the onset of an extensive chronic GVHD in one of them (UPN 13) (Figure 4 ). The incidence of chronic GVHD did not correlate with MRD status: 2/7 in MRD(−) vs 2/3 in MRD(+) patients. Although a MRD(−) CR was more frequent among patients developing acute GVHD (3/4 vs 2/6), this difference did not reach statistical significance (P = 0.23). When analyzed as time-dependent variable, no significant differences were encountered in the probability of achieving response at MRD level between allo and autotransplants (log-rank test, P = 0.76). None of the eight responders has experienced a clinical relapse after a median follow-up of 43 months (range, 15-106) and all patients but one continue to be MRD(−) at last follow-up. A transient reappearance of the CLL population was observed between 36 and 48 months post-transplant in one patient (UPN 5); this Results of MRD monitoring after allotransplantation. TRD, treatment-related deaths.
patient continues in CR without evidence of MRD at 60 months after transplant. In one of the three patients who died from transplant-related causes (UPN 2), MRD analysis performed at 3 months after transplant showed residual disease in the absence of clinically detectable features. Of note, this latter patient was still in clinical CR at the time of death, as assessed at necropsy.
Event-free survival (EFS) after auto and allotransplantation (P = NS) is shown in Figure 5 , which shows a plateau of 65% after allogeneic transplant with four patients in CR after more than 4 years post-transplant (range, 51-105 months). In addition, a higher probability of remaining in MRD(−) status was observed in patients after allotransplant as compared to autotransplant (7/7 vs 5/9 with a median duration of MDR response not reached vs 30 months after allo and autotransplant, respectively; log-rank test, P = 0.013).
Discussion
Despite some progress in therapy, CLL remains incurable with standard treatments. For this reason, the number of patients with CLL that are being transplanted is increasing. 4, 5 The impact of stem cell transplantation on the outcome of patients with CLL, however, is largely unknown. Likewise, predictors of the response and the outcome after transplantation have not been widely studied. 22, 23 Furthermore, the relationship
Figure 5
Event-free survival after autotransplant and allogeneic transplant, respectively. A disease-free plateau after allotransplant suggests the curation of a proportion of patients.
Stem cell transplants and MRD in CLL
between status of MRD and transplant results has only been analyzed in a few studies. [24] [25] [26] [27] [28] [29] In most series, the outcome of autologous transplants is strongly correlated with the status of the disease before transplantation. Not surprisingly, patients with sensitive disease respond better and have a much favorable outcome than patients transplanted with active, refractory disease. [22] [23] [24] [27] [28] [29] [30] [31] [32] This is confirmed in our series, in which all 14 patients that were autografted achieved CR, which, in nine cases, was accompanied by the absence of MRD, as studied by cytofluorometry and IgH gene analysis. However, most of the patients experience a relapse, with a recurrence rate of approximately 50% 4 years after transplantation. 23, 30, 31 In our group of patients, the relapse rate was 39% (s.e. ± 15) at 24 months. This suggests that in most instances autologous transplants do not cure the disease, although they could prolong overall survival. 23, 24, 29, 30 The results of this study also corroborate the importance of the status of MRD after transplantation. Thus, none of the patients who obtained CR at MRD level has relapsed after a median follow-up of 26 months (range, 9-50 months). However, the reappearance of MRD was observed in four of these patients at 6, 12, 30 and 42 months after transplantation, respectively. In contrast, a steady increase in the leukemic population was observed in patients in whom MRD could be demonstrated after transplantation, with four patients having had an overt clinical relapse at 9, 15, 17 and 18 months after transplant, respectively. As shown in Figure 3 , MRD 'relapse' seems to anticipate clinical relapse, an observation also pointed out in other studies. 22, 26 Taken together, these results suggest that achieving a MRD(−) status is critical to the outcome of autografted patients. For this reason, the investigation of strategies (eg purine analogues in combination with other drugs, Campath-1H) that have the potential to improve not only the response rate but also to eradicate MRD seems warranted. 33 In contrast with what can be seen in allografts, in no patient was a delayed negativization of MRD detected; this observation is in agreement with previous reports. 24, 26 On the other hand, in those cases in which MDR reappeared, the proportion of detectable leukemic cells usually increased over time and anticipated clinical relapse. Both findings, ie degree of response at MRD level and subsequent MRD follow-up, emphasize the importance of MRD studies as predictors of the outcome after autologous transplantation.
Allogeneic stem cell transplants, on the other hand, result in a TRM ranging from 25 to 50%, which is mostly due to GVHD and other complications. 5, 29, [34] [35] [36] In our series, TRM was 25%. In contrast to autologous transplants, in the majority of allotransplant series there is a survival plateau of 40 to 60%. 29, [34] [35] [36] The possibility of obtaining long-term responses without detectable MRD was confirmed in our series, in which four of 12 patients remain in CR after more than 50 months (range, 51-105 months). Interestingly, histologic transformation with a high p53 protein expression might be the mechanism responsible for the lack of response observed in the only patient refractory to allogeneic transplantation. Our results, as well as others, 5, 29, [34] [35] [36] strongly suggest that a fraction of CLL patients can be cured by allotransplantation. Of note, allogeneic transplants can induce sustained CR in patients refractory to treatment, including cases resistant to purine analogs; 29, 35 this is in contrast to results with autologous transplants, in which sensitivity of the disease to treatment is a necessary pre-requisite for the success of the procedure. 23 In this regard, a convincing graft-versus-CLL effect has been described in patients with active disease after allotransplantation who have achieved CR after either donor lymphocyte Leukemia infusions or suppression of immunosuppressive therapy. 37, 38 It is extremely likely that the better results observed with allogeneic transplants are due, at least in part, to a graft-versustumor effect. The observation of cases in which the detection of MRD is not accompanied by a clinical relapse, as was the case in one of our patients, is also most likely explained by the modulation of the graft-versus-tumor effect on the residual leukemic cells. In line with the above, there are a number of cases in which a delayed clearance of MRD, taking up to more than 1 year after transplant, has been observed. 25, 29, 39 This was also the case in two of our patients who did not achieve an MRD(−) status until 12 and 22 months after transplant, respectively; the chronic GVHD which one of these patients developed might have contributed to the deferred clearance of the MRD.
In agreement with other reports, it is apparent from our results that achieving an MRD(−) status is critical in the outcome of patients with CLL receiving stem cell transplants, particular autologous ones. 22, 24, 26 As far as the techniques used to detect MRD are concerned, specific probes designed from the particular IgH rearrangement in each patient is the most reliable method for detecting MRD, 24, 26 with a level of sensitivity of 10 −5 −10 −6 . Since this technique is not widely available, in most centers MRD detection is based on cytofluorometry and the study of the CDRIII region of the IgH gene using consensus primers, with a sensitivity of 10 . [16] [17] [18] [19] 33, [40] [41] [42] [43] [44] Of note, conventional cytofluorometric criteria may be misleading in the post-transplant period. Several circumstances, such as previous treatment with purine analogues, purging of the harvest and immunosuppressive agents given after transplantation, can result in an abnormal distribution of the lymphoid subsets. Thus, an excess of CD5-expressing B lymphocytes, as observed in our study, has been reported after both autologous and allogeneic transplants. 45 In this context, the finding of an expanded polyclonal B cell population in a patient who underwent an autologous transplant with a double selection of the harvest might be due to an abnormal lymphoid reconstitution. 46 A multiparametric analysis, as described here, allows better identification of the residual CLL clone. Moreover, as recently shown, real-time PCR assays may be helpful in analyzing the MRD kinetics. 47, 48 In summary, the present report suggests that in CLL patients the probability of obtaining sustained MRD(−) CR after autotransplantation is low and that MRD analysis is useful to predict clinical relapse. On the other hand, the long-lasting responses observed after allogeneic transplants indicate the possibility of a true eradication of CLL in a significant proportion of patients, although delayed responses or transient relapses at MRD level may be detected in some instances. A longer follow-up and quantitative techniques for MRD detection will be helpful not only to confirm the value of MRD assessment in the prediction of the outcome of stem cell transplants for CLL, but also to investigate treatment strategies aimed at achieving MRD(−) CR.
